The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) for refractory germ-cell tumors (GCT).
Yago Nieto
No relevant relationships to disclose
Nizar M. Tannir
No relevant relationships to disclose
Shi-Ming Tu
No relevant relationships to disclose
Roy B. Jones
No relevant relationships to disclose
Amado J. Zurita
No relevant relationships to disclose
Ana Aparicio
No relevant relationships to disclose
Roland Bassett
No relevant relationships to disclose
Kim Allyson Margolin
No relevant relationships to disclose
Leona Holmberg
No relevant relationships to disclose
Richard E. Champlin
No relevant relationships to disclose
Lance C. Pagliaro
No relevant relationships to disclose